Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA E545K PW12 cervical cancer sensitive detail...
PIK3CA mutant Cetuximab cervical cancer decreased response detail...
Unknown unknown Mps-BAY2b + Paclitaxel cervical cancer not applicable detail...
RB1 mut TP53 mut R547 cervical cancer sensitive detail...
Unknown unknown BIND-014 cervical cancer not applicable detail...
Unknown unknown Radiotherapy + TAS-116 cervical cancer not applicable detail...
Unknown unknown Tozasertib cervical cancer not applicable detail...
Unknown unknown BIRB-796 + Tozasertib cervical cancer not applicable detail...
Unknown unknown ETP-46464 + Radiotherapy cervical cancer not applicable detail...
Unknown unknown Cisplatin + ETP-46464 cervical cancer not applicable detail...
Unknown unknown Cisplatin + VE-821 cervical cancer not applicable detail...
AKT1 E17K Capivasertib cervical cancer predicted - sensitive detail...
Unknown unknown BMS-986205 + Nivolumab cervical cancer not applicable detail...
ERBB2 mutant Neratinib cervical cancer predicted - sensitive detail...
ERBB2 D769N Neratinib cervical cancer no benefit detail...
ERBB2 S310F Neratinib cervical cancer predicted - sensitive detail...
ERBB2 S310Y Neratinib cervical cancer predicted - resistant detail...
PIK3CA mutant Alpelisib cervical cancer predicted - sensitive detail...
Unknown unknown Tisotumab Vedotin cervical cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00292955 Phase II Cetuximab Cisplatin Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma Unknown status
NCT00980954 Phase III Carboplatin + Paclitaxel Cisplatin Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting
NCT01711515 Phase I Ipilimumab Cisplatin Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer Active, not recruiting
NCT01958112 Phase II Trametinib + Uprosertib GSK1120212+GSK2141795 for Cervical Cancer Terminated
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT02100007 Phase Ib/II ME-344 + Topotecan ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors Terminated
NCT02312804 Phase I Paclitaxel Carboplatin BGJ398 Ph Ib/BGJ398/Cervix and Other Solid Tumors Withdrawn
NCT02426892 Phase II Nivolumab Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors Active, not recruiting
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Recruiting
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated
NCT02487095 Phase Ib/II VX-970 Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Recruiting
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Recruiting
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02635360 Phase II Cisplatin Pembrolizumab Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer Recruiting
NCT02661815 Phase I Paclitaxel + Ricolinostat Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Active, not recruiting
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02812056 Phase I Alisertib + Sapanisertib Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Withdrawn
NCT02865135 Phase Ib/II Cyclophosphamide + DPX-E7 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Recruiting
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT03023319 Phase I Bosutinib + Pemetrexed Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting
NCT03104699 Phase Ib/II AGEN2034 Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer Recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03257267 Phase III Irinotecan Gemcitabine Vinorelbine Pemetrexed Cemiplimab Topotecan Study of REGN2810 in Adults With Cervical Cancer Recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03427411 Phase II M7824 Phase II Trial of M7824 in Subjects With HPV Positive Malignancies Recruiting
NCT03439085 Phase II Durvalumab + MEDI0457 Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers Recruiting
NCT03452332 Phase I Durvalumab + Tremelimumab Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar Cancer Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03527264 Phase II Cisplatin + Nivolumab BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03614949 Phase II Atezolizumab SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer Recruiting
NCT03618953 Phase I Ad-E6E7 + Atezolizumab + MG1-E6E7 This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers (Kingfisher) Active, not recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03968406 Phase I Talazoparib Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Not yet recruiting